Search for content, post, videos

Affibody presents long-term results with izokibep

Nikolai Brun
Affibody have shared long-term 46-week data from a global Phase 2 trial of izokibep in psoriatic arthritis (PsA). The randomized double-blind, placebo-controlled, Phase 2 clinical trial evaluated the safety and efficacy of izokibep dosed 80 mg every two weeks (Q2W) or 40 mg Q2W, versus placebo Q2
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.